fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Topiramate

All products: general benefit

Auro-Topiramate · DIN 02345838 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Topiramate · DIN 02345838 Manufacturer: Auro Pharma Inc.; listing date 2011-09-15 Health Canada: Marketed since 2020-03-31 · brand AURO-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Topiramate: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4583). What the ministry pays, not the patient.

Ministry pays: $0.4583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02345838)

Source record
DIN 02345838: Auro-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02345838 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83125
Interchangeable products
AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Apo-Topiramate · DIN 02279630 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583
Shortage status: resolved shortage (ended February 6, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02345838
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N03AX): coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, LAMOTRIGINE, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit (25), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 25mg, 100mg, 150mg · Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Epilepsy TOPAMAX® (topiramate) is indicated: • as monotherapy for the management of patients (adults and children six years and older) with newly diagnosed epilepsy. • as adjunctive therapy for the management of patients (adults and children two years and older) with epilepsy who are not satisfactorily controlled with conventional therapy. Migraine Prophylaxis Topamax is indicated in adults for the prophylaxis of migraine headache. Prophylactic treatment of migraine may be considered in situations such as: adults experiencing four or more migraine attacks per month who fail to respond adequately to acute abortive therapy; recurring attacks that significantly interfere with the patient’s daily routine; a pattern of increasing migraine attacks over time, with the risk of developing rebound headache from acute abortive therapies; or failure of, or contraindication to, or troublesome side effects from acute abortive medications. Continuing therapy should be reviewed every six months. Topamax should not be used in the acute treatment of migraine attacks. Safety and efficacy of topiramate in the management or prevention of cluster headache… https://pdf.hres.ca/dpd_pm/00081153.PDF PM date: 2025-07-23 Source product: TOPAMAX; DIN 02239907; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.